Bg pattern

ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops, solution

latanoprost/netarsudil

This medicinal product is subject to additional monitoring, which will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Roclanda and what is it used for
  2. What you need to know before you use Roclanda
  3. How to use Roclanda
  4. Possible side effects
  5. Storage of Roclanda
  6. Contents of the pack and other information

1. What is Roclanda and what is it used for

Roclanda contains the active substances latanoprost and netarsudil. Latanoprost belongs to a group of medicines called ‘prostaglandin analogues’. Netarsudil belongs to a group of medicines called ‘Rho kinase inhibitors’. They work in different ways to reduce the amount of fluid in the eye and lower the pressure.

Roclanda is used to reduce eye pressure in adults with a condition called ‘glaucoma’ or who have high pressure in the eye. If the pressure in the eye is too high, it can damage your sight.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Roclanda

Do not use Roclanda:

  • if you are allergic to latanoprost, to netarsudil or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Tell your doctor or pharmacist before you start using Roclanda if you think any of the following apply to you:

  • you have dry eye;
  • you have severe or uncontrolled asthma;
  • you have had or have a viral infection of the eye caused by the herpes simplex virus.

Do not use Roclanda more than once a day, as this may increase the risk of side effects.

Children and adolescents

Roclanda should not be used in children and adolescents under 18 years of age, as its safety and efficacy have not been established in this age group.

Other medicines and Roclanda

Roclanda may interact with other medicines. Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, especially if they contain another prostaglandin analogue, such as latanoprost.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Do not use Roclanda if you are pregnant.

Driving and using machines

You may notice blurred or altered vision just after using Roclanda. Do not drive or use machines until the symptoms have resolved.

Roclanda contains benzalkonium chloride

This medicine contains benzalkonium chloride, which may be absorbed by soft contact lenses and may change the colour of the contact lenses. Remove contact lenses before using this medicine and wait 15 minutes before putting them back.

Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other diseases of the cornea (the transparent layer on the front of the eye). Tell your doctor if you feel any unusual sensation, itching or pain in the eye after using this medicine.

3. How to use Roclanda

Use this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.

Roclanda is for use in the eyes only (ophthalmic use).

The recommended dose is one drop in each affected eye once a day, in the evening. Use the medicine at about the same time every day. Do not use it more than once a day.

Method of administration

Person tilting their head back while one hand holds a dropper bottle over their open eye

  • Wash your hands before using the medicine.
  • Do not touch the tip of the dropper with your fingers when opening or closing the bottle, as the eye drops may become contaminated.
  • Remove the cap from the bottle and place it on a clean surface. Continue to hold the bottle, making sure the tip does not touch anything.
  • Hold the bottle, pointing downwards, between your thumb and the other fingers.
  • Tilt your head back.
  • Pull down the lower eyelid to form a ‘pocket’ between the eyelid and the eye. The drop will go into this pocket.
  • Bring the tip of the dropper close to the eye. If it helps, you can do this in front of a mirror.
  • Do not touch the eyes, eyelids, or surrounding areas with the tip of the dropper, as the eye drops may become contaminated.
  • Gently squeeze the bottle to release one drop of Roclanda into the eye.
  • Release one drop at a time. If the drop does not go into the eye, try again.
  • Press the edge of the eye, next to the nose, for 1 minute. Keep the eye closed.
  • If you need to use the eye drops in both eyes, repeat the steps in the other eye while the bottle is open.
  • Replace the cap on the bottle to close it.
  • Put the bottle back in the carton to protect it from light until you need to use the eye drops again.

If you are using other eye drops, wait at least 5 minutes after using them before using Roclanda. If you use eye ointments, you should use them last.

If you use more Roclanda than you should

Rinse your eyes with warm water. Do not put in any more drops until the next normal dose is due.

If you forget to use Roclanda

Continue with the next dose as planned. Do not use a double dose to make up for a forgotten dose.

Do not use more than one drop once a day in the affected eye.

If you stop using Roclanda

Do not stop using Roclanda without talking to your doctor first. If you stop using Roclanda, your eye pressure will not be controlled, which could lead to loss of vision.

If you have any other questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been seen with Roclanda and with other medicines that contain latanoprost or netarsudil alone:

  • Very common (may affect more than 1 in 10 people)
  • Ocular effects:
  • eye redness; fine deposits in the front of the eye and pain at the drop administration site; gradual increase in brown pigmentation of the coloured part of the eye (the iris) which may result in a change in eye colour; gradual increase in colour (darkening), length, thickness and number of eyelashes.
  • Common (may affect up to 1 in 10 people)
  • Ocular effects:
  • eye infection or inflammation; dry eye or small breaks in the tear film on the surface of the eye; eye discharge; eyelid itching; blurred vision and slight decrease in vision; eye pain; feeling of something in the eye; general redness of the eyes shortly after putting in the drops; red spots or areas of redness on the eye; allergic conjunctivitis (inflammation of the eye or prominent blood vessels); watery eyes; swelling around the eye; crusts on the eyelid and blurred vision.
  • General side effects:
  • redness or itching of the skin of the face.
  • Uncommon (may affect up to 1 in 100 people)
  • Ocular effects:
  • increase in pressure of the fluid in the eye; inflammation of the coloured part of the eye (the iris); swelling of the iris; increase in wrinkles of the transparent layer on the front of the eye where it meets the lower eyelid; blindness; blurred vision, double vision or halo vision; blockage of the tear duct; small coloured spots on the surface of the eye; dryness of the eyelids; dry eye caused by inflammation of the glands in the eyelids; eye allergy; shiny eyes; tired eyes; numbness or burning in the eye; abnormal turning out of the lower eyelid; loss of eyelashes and diabetic eye disease; increased sensitivity to light; discolouration of the eyelid skin.
  • General side effects:
  • nose congestion; nosebleed; nasal discomfort and pain; headache; dizziness; vomiting; redness or itching of the skin; dry skin; thickening of the skin; muscle pain or spasms or weakness; joint pain; jaw pain; skin itching; inflammation of the cartilage; chest pain (angina); feeling your heartbeat (palpitations); asthma and difficulty breathing (dyspnoea).
  • Rare (may affect up to 1 in 1,000 people)
  • Ocular effects:
  • swelling or itching that causes damage to the surface of the eye; swelling around the eye (periorbital oedema); misdirected growth of eyelashes or growth of an extra row of eyelashes; scarring of the surface of the eye; accumulation of fluid in the coloured part of the eye (iris cyst); skin reactions on the eyelids; darkening of the eyelid skin and viral infection of the eye caused by the herpes simplex virus.
  • General side effects:
  • worsening of asthma; intense itching of the skin.
  • Very rare (may affect up to 1 in 10,000 people)
  • Ocular effects:
  • appearance of sunken eyes (increased depth of the eye socket).
  • General side effects:
  • worsening of angina in patients with heart disease.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Roclanda

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date is the last day of the month shown.

Unopened bottle: store in a refrigerator (between 2°C and 8°C).

Once the bottle is open: do not store above 25°C.

Store in the original carton to protect from light.

To avoid infections, discard the bottle 4 weeks after first opening and use a new bottle.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.

6. Contents of the pack and other information

What Roclanda contains

  • The active substances are latanoprost and netarsudil. Each ml of solution contains 50 micrograms of latanoprost and 200 micrograms of netarsudil (as mesilate).
  • The other ingredients are benzalkonium chloride (see ‘Roclanda contains benzalkonium chloride’ in section 2), mannitol, boric acid, sodium hydroxide (for pH adjustment) and water for injections.

Appearance and packaging

Roclanda is a clear liquid eye drop solution. It comes in a plastic bottle. Each bottle contains 2.5 ml of the medicine and each pack contains 1 or 3 bottles with a screw cap. Not all pack sizes may be marketed.

Marketing authorisation holder

Santen Oy

Niittyhaankatu 20, 33720 Tampere, Finland

Manufacturer

Aerie Pharmaceuticals Ireland, Limited

Athlone Business and Technology Park, Dublin Road,

Garrycastle, Athlone, Co Westmeath, N37 DW40, Ireland

and

Santen Oy

Kelloportinkatu 1, 33100 Tampere, Finland

For further information about this medicine, contact the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Santen Oy

Tél/Tel: +32 (0) 24019172

Lietuva

Santen Oy

Tel: +370 37 366628

Santen Oy

Тел.: +359 (0) 888 755 393

Luxembourg/Luxemburg

Santen Oy

Tél/Tel: +352 (0) 27862006

Ceská republika

Santen Oy

Tel: +358 (0) 3 284 8111

Magyarország

Santen Oy

Tel: +358 (0) 3 284 8111

Danmark

Santen Oy

Tlf: +45 898 713 35

Malta

Santen Oy

Tel: +358 (0) 3 284 8111

Deutschland

Santen GmbH

Tel: +49 (0) 3030809610

Nederland

Santen Oy

Tel: +31 (0) 207139206

Eesti

Santen Oy

Tel: +372 5067559

Norge

Santen Oy

Tlf: +47 21939612

Ελλάδα

Santen Oy

Τηλ: +358 (0) 3 284 8111

Österreich

Santen Oy

Tel: +43 (0) 720116199

España

Santen Pharmaceutical Spain S.L.

Tel: +34 914 142 485

Polska

Santen Oy

Tel.: +48(0) 221042096

France

Santen S.A.S.

Tél: +33 (0) 1 70 75 26 84

Portugal

Santen Oy

Tel: +351 308 805 912

Hrvatska

Santen Oy

Tel: +358 (0) 3 284 8111

Ireland

Santen Oy

Tel: +353 (0) 16950008

România

Santen Oy

Tel: +358 (0) 3 284 8111

Slovenija

Santen Oy

Tel: +358 (0) 3 284 8111

Ísland

Santen Oy

Sími: +358 (0) 3 284 8111

Slovenská republika

Santen Oy

Tel: +358 (0) 3 284 8111

Italia

Santen Italy S.r.l.

Tel: +39 0236009983

Suomi/Finland

Santen Oy

Puh/Tel: +358 (0) 974790211

Κύπρος

Santen Oy

Τηλ: +358 (0) 3 284 8111

Sverige

Santen Oy

Tel: +46 (0) 850598833

Latvija

Santen Oy

Tel: +371 677 917 80

United Kingdom (Northern Ireland)

Santen Oy

Tel: +353 (0) 16950008

(UK Tel: +44 (0) 345 075 4863)

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Online doctors for ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution

Discuss questions about ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution?
ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution?
The active ingredient in ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution is latanoprost and netarsudil. This information helps identify medicines with the same composition but different brand names.
Who manufactures ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution?
ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution is manufactured by Santen Oy. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ROCLANDA 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution?
Other medicines with the same active substance (latanoprost and netarsudil) include ABIPROST 0.3 mg/ml EYE DROPS SOLUTION IN SINGLE-DOSE CONTAINERS, AMIRIOX 0.3 mg/ml EYE DROPS SOLUTION, BIMATOPROST STADA 0.3 mg/ml EYE DROPS SOLUTION IN SINGLE-DOSE CONTAINERS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media